We know MRD detection is feasible and widely employed for hematological cancers… but what does the future hold for solid tumor MRD technologies? Written by Alex Kernagis, Rayna Saldanha, Claire Liddy and Bryan Kaplan.
The niche space of minimal residual disease testing is quickly growing within the world of biotech due to great strides in sequencing and biopsy technology development over the last decade. Minimal residual disease (MRD) is a term used to describe detectable residual fragments of cancer in patients who have had cancer treatment with a curative intent such as surgery or chemotherapy. …
Description: JHU’s newest student-run healthcare and life-sciences consulting group
An Exciting New Chapter
Cobalt Consulting Group was founded in 2020 to bridge the rapidly budding business community with the prestigious biomedical atmosphere of Johns Hopkins!
Cobalt is entirely operated by students at Johns Hopkins University, helping to advise innovative companies within the thriving industries of life-sciences and healthcare — historically consulting companies and startups that have brought in more than $200 million in grants and total venture funding to date.
Nearly half of our team comes with experience from the JHU Biomedical Engineering Department, the top BME program in the nation. All of our BME consultants have worked in disruptive design teams, and groundbreaking research labs, helping to carry the torch through the cutting-edge world of medicine and science. The rest of our team comes seasoned with work experience from the top consulting firms, financial institutions, Fortune 500 companies, and startups. This balance between business and science creates the perfect perspective and skillset to provide our clients with the expertise they need to tackle their issues and reach the next level, while fostering an environment that allows us to constantly learn from each other and be challenged. …